EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

PErsistence and Safety of Subcutaneous Infliximab 1 Year After Switch From Intravenous Route in IBD Patients in REMission

Nicolas Mathieu, Marianne Hupé, Frédéric Heluwaert, Pauline Rivière, Xavier Hébuterne, Antoine Chupin, Vered Abitbol, Guillaume Bouguen, Lucine Vuitton, Jean-Marc Gornet, Céline Montuclard, Stéphane Nancey und 21 weitere

Clinical Gastroenterology and Hepatology · 2025

DOI: 10.1016/j.cgh.2025.04.028 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2025. Verfasst von Nicolas Mathieu und 32 weiteren Autor:innen. Beteiligte Einrichtung: CNRS UMR 5309-INSERM U1209, Hepato-Gastroenterology and Digestive Oncology Department, Institute for Advanced Biosciences, CHU Grenoble Alpes, Univer…. Hauptthemen laut MEDLINE: Gastrointestinal Agents, Inflammatory Bowel Diseases, Infliximab. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Celltrion Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Real-life data regarding inflammatory bowel disease (IBD) evolution after switch from intravenous infliximab (IV-IFX) to subcutaneous infliximab (SC-IFX) is necessary. The aim of this prospective multicenter cohort study was to describe the persistence, effectiveness and tolerance of SC-IFX after switch from IV-IFX. METHODS: IBD patients in steroid-free clinical remission for at least 6 months on IV-IFX were enrolled in a prospective national French cohort when they switched to SC-IFX. Patients were assessed at inclusion and at weeks 12, 24, and 48. The primary endpoint was the persistence of SC-IFX at week 48. Secondary endpoints comprised steroid-free clinical remission at week 48, IV-IFX switch-back rate, and evolution of infliximab levels during the study period. RESULTS: Among the 426 patients included (72.4% with Crohn's disease , 27.5% with ulcerative colitis; 45.1% female; median age 37 [interquartile range, 29-50] years; median disease duration of 12 years in Crohn's disease, 13 years in ulcerative colitis), 56% were on IV-IFX standard dosing (5 mg/kg 8-weekly) and 16% received combination therapy with an immunomodulator drug at baseline. At week 48, SC-IFX persistence was 95.4% (95% confidence interval, 93.3%-97.5%) and 86.9% of patients were on steroid-free clinical remission. Mean infliximab levels were 8.0 μg/mL at inclusion and 18.0 μg/mL at week 48 (P < .0001). Among the 19 (4.5%) patients who stopped SC-IFX, 6 (1.4%) switched back to IV-IFX. There were 222 adverse events reported in 42.4% of patients, and 12 led to treatment discontinuation, including 6 (1.4%) severe adverse events. CONCLUSIONS: In this large multicenter prospective cohort, persistence at 1 year of SC-IFX was more than 95% of IBD patients switched in remission from IV-IFX, confirming excellent effectiveness and tolerance of SC-IFX.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal AgentsInflammatory Bowel DiseasesInfliximabAdultFemaleHumansMaleMiddle AgedAdministration, IntravenousFranceInjections, SubcutaneousProspective StudiesRemission InductionTreatment Outcome

Stichwörter der Autor:innen

Inflammatory Bowel DiseaseSubcutaneous InfliximabSwitch

Substanzen

Gastrointestinal AgentsInfliximab

Autor:innen und Institutionen

  • CNRS UMR 5309-INSERM U1209, Hepato-Gastroenterology and Digestive Oncology Department, Institute for Advanced Biosciences, CHU Grenoble Alpes, Université Grenoble Alpes, Grenoble, France; IBD Private Institute, Echiroll…
  • CNRS UMR 5309-INSERM U1209, Hepato-Gastroenterology and Digestive Oncology Department, Institute for Advanced Biosciences, CHU Grenoble Alpes, Université Grenoble Alpes, Grenoble, France.
  • Gastroenterology Unit, Centre Hospitalier Annecy Genevois, Épagny Metz-Tessy, France.
  • Service d'hépato-gastroentérologie, CMC Magellan, CHU de Bordeaux, Bordeaux, France.
  • Service de Gastro-entérologie et Nutrition, CHU de Nice et Université Côte d'Azur, Nice, France.
  • INSERM UMRS_938, Centre de Recherche Saint-Antoine, Department of Gastroenterology, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France.

Förderung

  • Celltrion Inc

Zitieren

APA

Mathieu, N., Hupé, M., Heluwaert, F., Rivière, P., Hébuterne, X., Chupin, A., Abitbol, V., Bouguen, G., Vuitton, L., Gornet, J. M., Montuclard, C., Nancey, S., Cadiot, G., Wils, P., Gilletta, C., de Maissin, A., Altwegg, R., Chanteloup, E., Plastaras, L., …, & Laharie, D. (2025). PErsistence and Safety of Subcutaneous Infliximab 1 Year After Switch From Intravenous Route in IBD Patients in REMission. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2025.04.028

Vancouver

Mathieu N, Hupé M, Heluwaert F, Rivière P, Hébuterne X, Chupin A, et al. PErsistence and Safety of Subcutaneous Infliximab 1 Year After Switch From Intravenous Route in IBD Patients in REMission. Clinical Gastroenterology and Hepatology. 2025. doi:10.1016/j.cgh.2025.04.028

BibTeX
@article{Mathieu2025,
  author = {Mathieu, Nicolas and Hupé, Marianne and Heluwaert, Frédéric and Rivière, Pauline and Hébuterne, Xavier and Chupin, Antoine and Abitbol, Vered and Bouguen, Guillaume and Vuitton, Lucine and Gornet, Jean-Marc and Montuclard, Céline and Nancey, Stéphane and Cadiot, Guillaume and Wils, Pauline and Gilletta, Cyrielle and de Maissin, Astrid and Altwegg, Romain and Chanteloup, Elise and Plastaras, Laurianne and Ah Soune, Philippe and Bourreille, Arnaud and Stefanescu, Carmen and Seksik, Philippe and Simon, Marion and Uzzan, Mathieu and Andrau, Pierre and Rouillon, Cléa and Arondel, Yves and Buisson, Anthony and Peyrin-Biroulet, Laurent and Mboup, Bassirou and Vicaut, Eric and Laharie, David},
  title = {PErsistence and Safety of Subcutaneous Infliximab 1 Year After Switch From Intravenous Route in IBD Patients in REMission},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2025},
  doi = {10.1016/j.cgh.2025.04.028}
}
Kostenlos starten →